OTX015 is primarily investigated for its potential in cancer therapy, particularly in targeting hematologic malignancies and solid tumors. It functions as a BET (bromodomain and extra-terminal) inhibitor, which plays a role in regulating gene expression. By inhibiting BET proteins, OTX015 disrupts the transcription of key oncogenes, leading to the suppression of tumor growth and proliferation. Its application is being explored in clinical trials for conditions such as acute leukemia, lymphoma, and certain types of breast and lung cancers. Additionally, its ability to modulate immune responses makes it a candidate for combination therapies with other anticancer agents, enhancing overall treatment efficacy.